Genzyme to supply less than half of EU demand for Thyrogen
This article was originally published in Scrip
Executive Summary
For the next several months, Genzyme will only be able to meet around 45% of the demand for its Thyrogen (thyrotropin alfa) in the EU, the company has warned the European Medicine Agency's Committee for Medicinal Products for Human Use (CHMP). The problem should be resolved by July when logistical issues connected with the transfer of manufacturing should be resolved.